A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1546-0096
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis ; volume:17 ; number:1 ; day:25 ; month:7 ; year:2019 ; pages:1-8 ; date:12.2019
Pediatric rheumatology ; 17, Heft 1 (25.7.2019), 1-8, 12.2019

Urheber
Bava, Cecilia
Mongelli, Federica
Pistorio, Angela
Bertamino, Marta
Bracciolini, Giulia
Dalprà, Sara
Davì, Sergio
Lanni, Stefano
Muratore, Valentina
Pederzoli, Silvia
Rosina, Silvia
Schiappapietra, Benedetta
Suffia, Chiara
Varnier, Giulia
Verazza, Sara
Giancane, Gabriella
Consolaro, Alessandro
Ravelli, Angelo
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1186/s12969-019-0355-0
URN
urn:nbn:de:101:1-2019121803364654956582
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:46 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Bava, Cecilia
  • Mongelli, Federica
  • Pistorio, Angela
  • Bertamino, Marta
  • Bracciolini, Giulia
  • Dalprà, Sara
  • Davì, Sergio
  • Lanni, Stefano
  • Muratore, Valentina
  • Pederzoli, Silvia
  • Rosina, Silvia
  • Schiappapietra, Benedetta
  • Suffia, Chiara
  • Varnier, Giulia
  • Verazza, Sara
  • Giancane, Gabriella
  • Consolaro, Alessandro
  • Ravelli, Angelo
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Combination Therapy for Psoriasis with Methotrexate and Other Oral Disease-Modifying Antirheumatic Drugs: A Systematic Review

Combination Therapy for Psoriasis with Methotrexate and Other Oral Disease-Modifying Antirheumatic Drugs: A Systematic Review

Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis

Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis

Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis

Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis

Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review

Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review

Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis

Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis

Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns Among Rheumatologists in Europe and Japan

Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns Among Rheumatologists in Europe and Japan

Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns for Rheumatoid Arthritis Among United States Physicians

Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns for Rheumatoid Arthritis Among United States Physicians

Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs

Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs

Methotrexate, Tofacitinib, and Biologic Disease-Modifying Antirheumatic Drug Safety and Effectiveness Among Patients with Rheumatoid Arthritis in Japan: CorEvitas Registry Observational Study

Methotrexate, Tofacitinib, and Biologic Disease-Modifying Antirheumatic Drug Safety and Effectiveness Among Patients with Rheumatoid Arthritis in Japan: CorEvitas Registry Observational Study

Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs : : a descriptive analysis of data from interventional trials and the real-world setting

Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs : : a descriptive analysis of data from interventional trials and the real-world setting

Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting

Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting

Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting

Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting

Verbundene Objekte